QuidelOrtho Corporation (QDEL)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

• Jahresbericht (10-K)

  Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

  Eingereicht am 2026-02-19

  Dokument ansehen

• Quartalsbericht (10-Q)

  Ein Update zur finanziellen Entwicklung der letzten drei Monate.

  Eingereicht am 2026-08-07

  Dokument ansehen

• Ad-hoc-Meldung (8-K)

  Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

  Eingereicht am 2026-09-23

  Dokument ansehen

• 4/16/2026NEGATIVE
  QuidelOrtho Stock Sinks To 52-Week Low - Here's Why

  QuidelOrtho Inc. (QDEL) shares plummeted to a 52-week low following the company's announcement of Q1 revenue falling short of expectations, projected between $615 million and $620 million. The company cited significant headwinds, including challenges in the Chinese market and an unusually mild flu season, which directly impacted sales volumes. This revenue miss, coupled with a substantial 32% stock decline, signals considerable operational and market challenges for the diagnostics company. Investors are closely monitoring management's strategy to navigate these difficulties and restore growth momentum.

• 3/9/2026POSITIVE
  Rice Hall James Buys QuidelOrtho Stock

  Institutional investor Rice Hall James has disclosed a significant purchase of QuidelOrtho stock, signaling strong conviction in the company's future prospects. QuidelOrtho, a global leader in diagnostic technologies for healthcare providers, operates across labs, clinics, and retail settings. This strategic investment by a notable fund manager suggests an expectation of positive performance, potentially driven by anticipated growth in the diagnostics market or specific company catalysts. Investors will monitor QuidelOrtho's upcoming financial reports and strategic announcements for validation of this positive sentiment.

• 3/2/2026POSITIVE
  QuidelOrtho Corp Director Purchases 10k Shares as CFO Retires

  Markets Gazette reports a potentially bullish signal for QuidelOrtho Corporation (QDEL). Despite a multi-year decline in the stock and the recent announcement of the CFO's retirement, a board member has purchased a significant 10,000 shares of the company. This move, coming from an insider with deep knowledge of the company's dynamics, could indicate internal confidence in the firm's ability to reverse its fortunes. Investors will be closely watching whether this substantial insider purchase might foreshadow a turnaround for the stock, which has struggled to gain momentum in recent years. Insider optimism often acts as a catalyst for market sentiment.